Brian Daniels

Brian F.
Daniels currently works at Artiva Biotherapeutics, Inc., as Chairman from 2020, RareCyte, Inc., as Director, Inipharm, Inc., as Director from 2020, Transcelerate Biopharma, Inc., as Director, Medarex, Inc., as Director from 2009, Apexigen, Inc., as Advisor, and 5AM Venture Management LLC, as Venture Partner from 2014.
Dr. Daniels also formerly worked at Nohla Therapeutics, Inc., as Non-Executive Director, IDEAYA Biosciences, Inc., as Independent Director, Novo Nordisk Ltd., as Director, Spyryx Biosciences, Inc., as Director, Novo Nordisk A, as Independent Director from 2016 to 2021, Armaron Bio Ltd., as Director, Cabaletta Bio, Inc., as Independent Director from 2018 to 2021, Merck Research Laboratories Massachusetts LLC, as Principal, The Boston Consulting Group, as Senior Advisor from 2015 to 2018, Genentech, Inc., as Principal, and Bristol Myers Squibb Co., as Senior Vice President-Global Development from 2004 to 2014.
Dr. Daniels received his undergraduate degree in 1981 and graduate degree in 1981 from Massachusetts Institute of Technology and doctorate degree in 1987 from Washington University School of Medicine.